DiaSorin S.p.A. (OTCMKTS:DSRLF) Receives Consensus Rating of “Hold” from Analysts

Shares of DiaSorin S.p.A. (OTCMKTS:DSRLF) have been assigned an average rating of “Hold” from the six ratings firms that are currently covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company.

DSRLF has been the subject of several recent analyst reports. Zacks Research raised shares of DiaSorin to a “hold” rating in a report on Tuesday, May 12th. BNP Paribas Exane raised shares of DiaSorin to a “neutral” rating in a research report on Wednesday, January 28th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of DiaSorin in a report on Tuesday, February 10th. Finally, UBS Group lowered DiaSorin from a “buy” rating to a “neutral” rating in a research note on Thursday, April 9th.

DiaSorin Stock Performance

Shares of DSRLF stock opened at $67.00 on Thursday. DiaSorin has a 12 month low of $66.50 and a 12 month high of $112.30. The business’s 50 day moving average is $70.71 and its two-hundred day moving average is $75.34.

About DiaSorin

DiaSorin S.p.A. is an Italy?based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over?the?counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.